Condition: Non-small Cell Lung Cancer Stage IIIC · Non-small Cell Lung Cancer Stage IV · Non Small Cell Lung Cancer · Sponsor: University of California, Davis
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
This description comes directly from the study's public registry record.
Surbhi Singhal, MD · (916) 734-3772 · susinghal@health.ucdavis.edu
Always discuss trial participation with your own doctor first.
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07250477